Rates of early mortality, febrile neutropenia, infection, and length of stays
| . | Combined cohort (n = 656) . | . | |
|---|---|---|---|
| CPX-351 (n = 217) . | ven/aza (n = 439) . | P . | |
| Median cycles (range) | 2 (1-5) | 4 (1-28) | Not applicable |
| 30-day mortality, % (95% CI) | 5% (2%-8%) | 5% (3%-7%) | .51 |
| 60-day mortality, % (95% CI) | 10% (6%-14% | 13% (10%-16%) | .10 |
| Diagnosis of infection,* % (95% CI) | 51% (42%-61%) | 20% (15%-25%) | <.00005 |
| . | Combined cohort (n = 656) . | . | |
|---|---|---|---|
| CPX-351 (n = 217) . | ven/aza (n = 439) . | P . | |
| Median cycles (range) | 2 (1-5) | 4 (1-28) | Not applicable |
| 30-day mortality, % (95% CI) | 5% (2%-8%) | 5% (3%-7%) | .51 |
| 60-day mortality, % (95% CI) | 10% (6%-14% | 13% (10%-16%) | .10 |
| Diagnosis of infection,* % (95% CI) | 51% (42%-61%) | 20% (15%-25%) | <.00005 |
| . | HUP cohort (n = 111) . | . | |
|---|---|---|---|
| CPX-351 (n = 52) . | ven/aza (n = 59) . | . | |
| Febrile neutropenia % (95% CI) | 90% (82%-98%) | 54% (42%-67%) | <.00005 |
| Culture positive infection % (95% CI) | 67% (55%-80%) | 36% (23-48%) | .0004 |
| Mean days of inpatient stay† (95% CI) | 41 (37-45) | 15 (10-20) | <.00005 |
| . | HUP cohort (n = 111) . | . | |
|---|---|---|---|
| CPX-351 (n = 52) . | ven/aza (n = 59) . | . | |
| Febrile neutropenia % (95% CI) | 90% (82%-98%) | 54% (42%-67%) | <.00005 |
| Culture positive infection % (95% CI) | 67% (55%-80%) | 36% (23-48%) | .0004 |
| Mean days of inpatient stay† (95% CI) | 41 (37-45) | 15 (10-20) | <.00005 |